Strategy

Our goal is to be a leading specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates in the fields of psychiatry and neurology. Our near-term focus is on seeking regulatory approval and commercializing SILENOR™ (doxepin HCl tablets). The New Drug Application (NDA) for SILENOR™ was submitted January 31, 2008. We may in the future seek to advance our other product candidates and build a portfolio of product candidates that are currently commercialized outside the United States, approved in the United States but with significant commercial potential for proprietary new uses, new dosages or alternative delivery systems, or in late stages of development.